Yagmur U. Doruk

University of California, San Francisco — United States

Medicine · Health Sciences

7h-index279citations24works3.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

PARP inhibition in cancer therapy(10), Calcium signaling and nucleotide metabolism(7), interferon and immune responses(6), RNA regulation and disease(6), Protein Structure and Dynamics(5)

Publications24 total

Large scale prospective evaluation of co-folding across 557 Mac1-ligand complexes and three virtual screens
2025· 2 citedOpen Access
Author response: The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2
2025Open Access
The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2
eLife·2025Open Access
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2
2025· 1 citedOpen Access
Author response: The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2
2025Open Access
Exploration of structure-activity relationships for the SARS-CoV-2 macrodomain from shape-based fragment linking and active learning
Science Advances·2025· 14 citedOpen Access
Discovery of a Novel [6–6–5–5–6] Pentacyclic Tetrahydrocyclopentaphthalazinone as a Promising PARP Inhibitor Scaffold
ACS Medicinal Chemistry Letters·2025· 1 cited
Author response: The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2
2025Open Access
The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2
eLife·2025· 2 citedOpen Access
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2
2025· 2 citedOpen Access
Extensive exploration of structure activity relationships for the SARS-CoV-2 macrodomain from shape-based fragment merging and active learning
2024· 9 citedOpen Access
The Mac1 ADP-ribosylhydrolase is a Therapeutic Target for SARS-CoV-2
2024· 12 citedOpen Access
Supplementary Figure from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2
2023Open Access
Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2
2023Open Access
Supplementary Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2
2023Open Access
Supplementary Figure from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2
2023Open Access
Supplementary Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2
2023Open Access
Supplementary Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2
2023Open Access
Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2
2023Open Access
Supplementary Data from Resistance to ATR Inhibitors Is Mediated by Loss of the Nonsense-Mediated Decay Factor UPF2
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Morgan E. Diolaiti(21), Alan Ashworth(21), Patrick C. O’Leary(17), Danielle L. Swaney(17), Nevan J. Krogan(17), Huadong Chen(14), G.J. Correy(13), Moira Rachman(13), Adam R. Renslo(12), Brian K. Shoichet(12), James S. Fraser(12), Takaya Togo(11), Priyadarshini Jaishankar(11), R. Jeffrey Neitz(10), Maisie GV Stevens(10), Tess Williamson(9), Benjamin J. Polacco(9), Andrew S. McNeal(9), Tanushree Shenoy(9), Nupura Kale(9)